for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Carl Zeiss Meditec AG

AFXG.DE

Latest Trade

114.30EUR

Change

11.20(+10.86%)

Volume

405,833

Today's Range

105.10

 - 

114.70

52 Week Range

65.80

 - 

114.70

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
103.10
Open
105.10
Volume
405,833
3M AVG Volume
3.00
Today's High
114.70
Today's Low
105.10
52 Week High
114.70
52 Week Low
65.80
Shares Out (MIL)
89.44
Market Cap (MIL)
9,221.32
Forward P/E
45.08
Dividend (Yield %)
0.53

Next Event

Q1 2020 Carl Zeiss Meditec AG Earnings Release

Latest Developments

More

Carl Zeiss Meditec FY EBIT At EUR 264.7 Mln

Carl Zeiss Meditec FY EBIT Up At EUR 264 Million

Carl Zeiss Meditec Says 9M Revenues Up 10.9% To 1.03 Bln Euros

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Carl Zeiss Meditec AG

Carl Zeiss Meditec AG is a Germany-based medical technology and device company. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for microsurgery and other technologies, such as intraoperative radiotherapy. The Company operates in two segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment comprises activities in the area of ophthalmology, such as intraocular lenses, surgical visualization solutions and medical laser and diagnostic systems. The Microsurgery segment includes activities of neuro, ear, nose and throat surgery, as well as the activities in the field of intraoperative radiation. The Company has various production sites in Europe, the United States and Asia.

Industry

Computer Services

Contact Info

Goeschwitzer Strasse 51-52

+49.3641.2200

https://www.zeiss.de/meditec-ag/

Executive Leadership

Michael Kaschke

Chairman of the Supervisory Board

Ludwin Monz

Chairman of the Management Board, Chief Executive Officer

Tania von der Goltz

Independent Vice Chairman of the Supervisory Board

Justus Felix Wehmer

Chief Financial Officer, Member of the Management Board

Jan Willem de Cler

Chief Human Resource Officer and Employee Development, Member of the Management Board

Key Stats

2.71 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

1.2K

2018

1.3K

2019

1.5K

2020(E)

1.6K
EPS (EUR)

2017

1.570

2018

1.410

2019

1.790

2020(E)

2.279
Price To Earnings (TTM)
57.74
Price To Sales (TTM)
6.32
Price To Book (MRQ)
6.59
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
13.73
LT Debt To Equity (MRQ)
10.86
Return on Investment (TTM)
10.62
Return on Equity (TTM)
8.72

Latest News

Latest News

CORRECTED-(OFFICIAL)-BRIEF-Carl Zeiss Meditec To Be Included In German MDAX Midcap Index

* CARL ZEISS MEDITEC WILL IN MDAX REPLACE CTS EVENTIM , WHICH WILL BE INCLUDED IN SMALLCAP SDAX INDEX

BRIEF-Carl Zeiss Meditec Sees FY Adj EBIT Margin At 14-16 Pct

* DGAP-NEWS: CARL ZEISS MEDITEC AG STARTS NEW FISCAL YEAR 2017/18 WITH SOLID REVENUE GROWTH

BRIEF-Carl Zeiss Meditec FY Revenue Up By 9.3% To EUR 1.20 Bln

* SEES ADJUSTED EBIT MARGIN OF BETWEEN 14% AND 16% IN FISCAL YEAR 2017/18 AND IN MEDIUM TERM Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Carl Zeiss Meditec: ‍acquisition of Veracity Innovations​

* ACQUISITION OF VERACITY INNOVATIONS, LLC Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Valeant in talks to sell eye-surgery assets to Carl Zeiss: Bloomberg

Canadian drugmaker Valeant Pharmaceuticals International Inc <VRX.TO> <VRX.N> is in talks to sell its Bausch & Lomb unit's surgical products business to Germany's Carl Zeiss Meditec AG <AFXG.DE>, Bloomberg reported.

Valeant in talks to sell eye surgical products business - Bbg

Canadian drugmaker Valeant Pharmaceuticals International Inc is in talks to sell its Bausch & Lomb unit's surgical products business to Germany's Carl Zeiss Meditec AG, Bloomberg reported.

CORRECTED-BRIEF-Carl Zeiss Meditec H1 EBIT up 26 pct

* Adjusted EBIT margin increased to 15.2 percent (prior year: 14.3 percent)

BRIEF-Carl Zeiss Meditec prelim H1 revenue up at EUR 588 mln

* Achieves first half 2016/17 revenue of approximately 580 million euros ($618.16 million)

BRIEF-Carl Zeiss Meditec wins patent infringement action on trifocal intraocular lens

* Wins patent infringement action on trifocal intraocular lens against VSY Biotechnology and Fritz Ruck Ophthalmologische Systeme GmbH Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Carl Zeiss Meditec plans share issue to raise 300 million euros

German medical technology company Carl Zeiss Meditec <AFXG.DE> said it is to raise 300 million euros (266 million pounds) in a share issue to help finance acquisitions.

BRIEF-Carl Zeiss Meditec Q1 ebit 44.2 mln eur

* Says revenue increased by 6.6 percent (adjusted for currency effects: 5.4 percent), to eur280.0m (prior year: eur262.6m).

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up